Full Press Release Details
Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211.
LXRX
Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211
Key Takeaway: Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211